Your text is better than most. Not to worry, all good. Thanks for your kind words. OCX has produced a significant disappointment, back in 2019. The stock has recovered, but I'm uncertain about their future. As for LCTX, they've done quite nicely, in recent history. The stock has done well, and I think, it still has potential. Their top-of-the-line product shows great promise in regenerating the eye, and restore vision. They've already treated a patient in Israel, on a compassionate-use basis. The trials are going well. I'd be pleased, if you got something out of this, for your personal medical benefit. The field is making rapid progress. I think, both AgeX and LCTX are good choices. It's difficult to predict, how far and how fast the stock will come. Things can often change, very rapidly. But in both cases, I'm optimistic about their respective projects. Good luck to you!